Collaborations Pharmaceuticals, Inc. Awarded a New Grant to Develop MegaTox, Machine Learning Models for Toxicity Prediction 

Raleigh, North Carolina – The National Institute of Environmental Health Sciences (NIEHS) at the National Institutes of Health (NIH) has awarded an SBIR grant in the amount of $224,548 to Collaborations Pharmaceuticals, Inc. to provide and validate toxicity machine learning models using different algorithms for in vitroandin vivodatasets. 

 “We are honored to be awarded this grant as we have been working for several years to build up a series of validated machine learning models for different toxicity properties. We will curate and build a collection of tens of models which we have termed MegaTox, and deliver them to potential customers. This technology will also be used in our consulting projects with pharmaceutical and consumer product companies.” said Sean Ekins, PhD, chief executive officer of CPI.”

 “Considerable progress has been made in computational toxicology in a decade both in model development and availability such that MegaTox represents the next generation of larger scale models. Our efforts will focus on selected in vitroand in vivotesting to verify our predictions with the models and validate them further. MegaTox builds on our recent work generating machine learning models for the estrogen receptor which will be presented by Ms. Kimberley Zorn at the upcoming Society of Experimental Toxicology and Chemistry (SETAC) meeting.” Ekins said. 

“Research reported in this publication was supported by the National Institute Of Environmental Health Sciences of the National Institutes of Health under Award Number R43ES031038. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

About Collaborations Pharmaceuticals, Inc.

Collaborations Pharmaceuticals, Inc. performs research and development on innovative therapeutics for multiple rare and infectious diseases. We partner with academics or companies to identify and translate early preclinical to clinical stage assets. We have considerable experience of preclinical and computational approaches to drug discovery and toxicity prediction. We apply our various software tools for data curation and machine learning as represented by Assay Central (www.assaycentral.org), MegaTrans, MegaPredict, MegaTox.

For more information, please visit http://www.collaborationspharma.com/

Contact information CPI

Sean Ekins, Ph.D., D.Sc.

CEO and Founder,

Collaborations Pharmaceuticals, Inc.

840 Main Campus Drive, Lab 3510,

Raleigh, NC 27606

collaborationspharma@gmail.com

Tel 215-687-1320